The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes

Bibliographic Details
Main Authors:	Coll, Rebecca C., O'Neill, Luke A. J.
Format:	Online
Language:	English
Published:	Public Library of Science 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245271/

Similar Items

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
by: Coll, Rebecca C., et al.
Published: (2013)

Correction: The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
by: Coll, Rebecca C., et al.
Published: (2013)

Prion Pathogenesis in the Absence of NLRP3/ASC Inflammasomes
by: Nuvolone, Mario, et al.
Published: (2015)

Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis
by: Chung, I-Che, et al.
Published: (2016)

A Yersinia Effector with Enhanced Inhibitory Activity on the NF-κB Pathway Activates the NLRP3/ASC/Caspase-1 Inflammasome in Macrophages
by: Zheng, Ying, et al.
Published: (2011)

Anti-GBM Glomerulonephritis Involves IL-1 but Is Independent of NLRP3/ASC Inflammasome-Mediated Activation of Caspase-1
by: Lichtnekert, Julia, et al.
Published: (2011)

Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
by: Birnbaum, Yochai, et al.
Published: (2016)

Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout
by: Lee, Hye Eun, et al.
Published: (2016)

The role of the NLRP3 inflammasome in gout
by: Kingsbury, Sarah R, et al.
Published: (2011)

The Role of the NLRP3 Inflammasome in Fibrosis
by: Artlett, Carol M
Published: (2012)

NLRP3 Inflammasome and MS/EAE
by: Inoue, Makoto, et al.
Published: (2013)

NLRP3 Inflammasome and Pathobiology in AMD
by: Celkova, Lucia, et al.
Published: (2015)

ATP release and purinergic signaling in NLRP3 inflammasome activation
by: Gombault, Aurélie, et al.
Published: (2013)

Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells
by: Hillegass, Jedd M, et al.
Published: (2013)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
by: Saresella, Marina, et al.
Published: (2016)

Limited role for ASC and NLRP3 during in vivo Salmonella Typhimurium infection
by: De Jong, Hanna K, et al.
Published: (2014)

Questions and controversies in innate immune research: what is the physiological role of NLRP3?
by: Coll, RC, et al.
Published: (2016)

Role of the Nlrp3 Inflammasome in Microbial Infection
by: Anand, Paras K., et al.
Published: (2011)

NLRP3 Inflammasome Activation by Paracoccidioides brasiliensis
by: Tavares, Aldo Henrique, et al.
Published: (2013)

Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases
by: Bo-Zong Shao, et al.
Published: (2018-09-01)

NLRP3 Inflammasome Activation by Viroporins of Animal Viruses
by: Guo, Hui-Chen, et al.
Published: (2015)

Cytochrome c Negatively Regulates NLRP3 Inflammasomes
by: Shi, Chong-Shan, et al.
Published: (2016)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
by: Wan, Xingyong, et al.
Published: (2016)

NLRP3 inflammasome and its inhibitors: a review
by: Shao, Bo-Zong, et al.
Published: (2015)

Fatty acid synthesis and NLRP3-inflammasome
by: Moon, Jong-Seok, et al.
Published: (2015)

Vimentin regulates activation of the NLRP3 inflammasome
by: dos Santos, Gimena, et al.
Published: (2015)

NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis
by: Paramel Varghese, Geena, et al.
Published: (2016)

Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation
by: Van Opdenbosch, Nina, et al.
Published: (2014)

Ethanol Inhibits Activation of NLRP3 and AIM2 Inflammasomes in Human Macrophages–A Novel Anti-Inflammatory Action of Alcohol
by: Nurmi, Katariina, et al.
Published: (2013)

PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation
by: Xie, Min, et al.
Published: (2016)

Correction: Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1
by: Zorman, Jernej, et al.
Published: (2016)

Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1
by: Zorman, Jernej, et al.
Published: (2016)

Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation
by: Panchanathan, Ravichandran, et al.
Published: (2016)

An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes
by: Grinstein, L, et al.
Published: (2015)

AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC
by: Hornung, Veit, et al.
Published: (2009)

Inflammasome components ASC and AIM2 modulate the acute phase of biomaterial implant-induced foreign body responses
by: Christo, Susan N., et al.
Published: (2016)

The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3
by: Song, Hui, et al.
Published: (2016)

Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome
by: Yang, Chul-Su, et al.
Published: (2015)

Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines
by: Dashdorj, Amarjargal, et al.
Published: (2013)

Cytokine Profile in a Cohort of Healthy Blood Donors Carrying Polymorphisms in Genes Encoding the NLRP3 Inflammasome
by: Sahdo, Berolla, et al.
Published: (2013)